These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33058344)

  • 1. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register.
    Lepore V; Bosetti C; Santucci C; Iaffaldano P; Trojano M; Mosconi P;
    Eur J Neurol; 2021 Feb; 28(2):567-578. PubMed ID: 33058344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
    Kappos L; Butzkueven H; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S; Trojano M;
    Mult Scler; 2018 Jun; 24(7):963-973. PubMed ID: 28554238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
    Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR
    Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
    Lorefice L; Ferraro OE; Fenu G; Amato MP; Bresciamorra V; Conte A; De Luca G; Ferraro D; Filippi M; Gazzola P; Iaffaldano P; Inglese M; Lus G; Marfia GA; Patti F; Pesci I; Salemi G; Trojano M; Zaffaroni M; Monti MC; Cocco E;
    J Neurol; 2024 Apr; 271(4):1630-1637. PubMed ID: 38172380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
    Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
    Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
    Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
    Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
    López-Real AM; Gonzalez I; Solar DM; Oterino A; Costa E; Pato A; Llaneza MA; García-Estévez DA; Rodriguez-Regal A; Rodriguez M; Peña J
    Mult Scler Relat Disord; 2023 Jul; 75():104762. PubMed ID: 37229800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worsening of disability caused by relapses in multiple sclerosis: A different approach.
    Koch-Henriksen N; Thygesen LC; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2019 Jul; 32():1-8. PubMed ID: 31003200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.
    Ingwersen J; Masanneck L; Pawlitzki M; Samadzadeh S; Weise M; Aktas O; Meuth SG; Albrecht P
    Sci Rep; 2023 Sep; 13(1):15003. PubMed ID: 37696848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
    Bucello S; Annovazzi P; Ragonese P; Altieri M; Barcella V; Bergamaschi R; Bianchi A; Borriello G; Buscarinu MC; Callari G; Capobianco M; Capone F; Cavalla P; Cavarretta R; Cortese A; De Luca G; Di Filippo M; Dattola V; Fantozzi R; Ferraro E; Filippi MM; Gasperini C; Grimaldi LME; Landi D; Re ML; Mallucci G; Manganotti P; Marfia GA; Mirabella M; Perini P; Pisa M; Realmuto S; Russo M; Tomassini V; Torri-Clerici VLA; Zaffaroni M; Zuliani C; Zywicki S; Filippi M; Prosperini L
    J Neurol; 2021 Aug; 268(8):2922-2932. PubMed ID: 33616742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
    Costa-Frossard França L; Meca Lallana V; Labiano-Fontcuberta A; Blasco R; Monreal E; Martínez Ginés ML; Aguirre C; Sabin Muñoz J; Sainz de la Maza S; Cuello JP; Díaz-Pérez C; Chico García JL; Lozano Ros A; Rodríguez Jorge F; Martínez Martínez S; García Domínguez JM
    CNS Drugs; 2024 Mar; 38(3):231-238. PubMed ID: 38418770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
    Portaccio E; Betti M; De Meo E; Addazio I; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Torri Clerici V; Protti A; Ferraro D; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Comi G; Filippi M; Trojano M; Amato MP;
    J Neurol; 2024 Aug; 271(8):5074-5082. PubMed ID: 38805052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.
    Koch MW; Mostert J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Strijbis E; Cutter G
    Eur J Neurol; 2022 Apr; 29(4):1106-1116. PubMed ID: 34927308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
    Simone M; Lucisano G; Guerra T; Paolicelli D; Rocca MA; Brescia Morra V; Patti F; Annovazzi P; Gasperini C; De Luca G; Ferraro D; Margari L; Granella F; Pozzilli C; Romano S; Perini P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Lugaresi A; Portaccio E; Filippi M; Amato MP; Iaffaldano P;
    J Neurol; 2024 Oct; 271(10):6782-6790. PubMed ID: 39179712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.
    Cavallari M; Palotai M; Glanz BI; Egorova S; Prieto JC; Healy BC; Chitnis T; Guttmann CR
    Mult Scler; 2016 Dec; 22(14):1841-1849. PubMed ID: 26920374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between sustained disability progression and functional system scores in relapsing-remitting multiple sclerosis: analysis of placebo data from four randomized clinical trials.
    Scott T; Wang P; You X; Mann M; Sperling B
    Neuroepidemiology; 2015; 44(1):16-23. PubMed ID: 25634764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.
    Liu C; Blumhardt LD
    J Neurol Neurosurg Psychiatry; 2000 Apr; 68(4):450-7. PubMed ID: 10727480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.